Phase 4 N=94 Oral Nutrition After Regular Radical Cystectomy
Post Cystostomy
Primary: the Postoperative Length of Stay — 18; 14 day — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=84 Treatment for Acute Postoperative Voiding Dysfunction
Urinary Retention
Primary: Persistent Retention — 29; 21 participants
N/A N=34 Steps to Eliminate Postoperative Problems
Bladder Cancer
Primary: Number of Days Step Goal Completed — 4.5; 9 days
N/A N=142 Optimal Duration of Indwelling Urinary Catheter Following Pelvic Surgery
Urinary Retention
Primary: Number of Participants With Acute Urinary Retention — 6; 7 Participants
N/A N=90 Ureteral Stents Versus Percutaneous Nephrostomy for Initial Urinary Drainage
Children · Obstructive Uropathy · Acute Renal Failure
Primary: Period to Return to Normal Creatinine — 2.22; 2.18 days
N/A N=73 Real-world Evidence Study on Cystistat
Interstitial Cystitis and Bladder Pain Syndrome
Primary: Patient Global Assessment (PGA) — 90.1 percentage of participants (%)
N/A N=66 "Laparoscopic" Cystoscopy Versus Traditional Cystoscopy
Lower Urinary Tract Injury
Primary: Time Required to Perform Procedure (in Seconds) — 137; 451 seconds
Phase 4 N=242 Cytoscopic Antibiotic Irrigant to Reduce Postoperative Urinary Tract Infection
Urinary Tract Infections
Primary: Urinary Tract Infection — 11; 12 UTI
N/A N=49 Patient-operated Valved Catheter Versus Indwelling Transurethral Catheter
Bladder Dysfunction · Urinary Retention
Primary: Total Catheter Related Pain — 1.25; 2.3 units on a scale
N/A N=122 Trendelenburg, Abdominal Insufflation and Time to Completion of Cystoscopy
Bladder Integrity · Bladder Function · Ureteral Integrity
Primary: Time in Seconds to Complete the Cystourethroscopy — 103; 117; 147; 82 seconds
N/A N=214 Cystoinflation to Prevent Bladder Injury in Obstetrics and Gynaecology Surgery
Bladder Injury · Complications; Cesarean Section · Adhesions Pelvic
Primary: Bladder Injury Rate — 3; 22 Participants — p=<.0001
N/A N=219 Antibiotic Prophylaxis in Percutaneous Nephrostomy Placements and Replacements for Malignant Urinary Tract Obstruction
Ureteral Obstruction · Neoplasms · Acute Kidney Injury
Primary: Urinary Tract Infection After Percutaneous Nephrostomy Procedure — 5; 10 Percutaneous nephrostomy procedure — p=0.548
N/A N=84 Urinary Retention After Total Laparoscopic Hysterectomy With Immediate Foley Catheter Removal Versus Backfill Void Trial
Urinary Retention · Voiding Disorders
Primary: Number of Participants With Void Trial Failure Rate — 7; 11 Participants
N/A N=158 Self-discontinuation of a Transurethral Catheter
Postoperative Urinary Retention
Primary: Number of Participants With Postoperative Urinary Retention — 11; 11 Participants — p=0.5
Phase 4 N=181 Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction
Ureteral Obstruction
Primary: Ureteral Stent Symptom Questionnaire Score Up to 24 Hours Prior to Stent Insertion — 1.76; 1.84; 2.02; 1.93 score on a scale
N/A N=199 Patient Satisfaction Study: Clean Intermittent Self-Catheterization Teaching
Anxiety
Primary: State-Trait Anxiety Inventory-State Scores — 37.9; 40.7; NA; 37.7 units on a scale
Phase 4 N=98 Assessing Pyridium for Post-Sling Urinary Retention
Urinary Retention
Primary: Number of Participants Considered to Have Passed Their Voiding Trial — 30; 30 Participants
Phase 4 N=27 A Randomised Cross-over Study With Two 1-piece Urostomy Bags.
Urostomy
Primary: Preference of Sensura vs Moderma — 45; 43 percentage of prefering the product
N/A N=69 Assessment of Two Postoperative Techniques Used to Predict Voiding Efficiency After Gynecologic Surgery
Urinary Incontinence
Primary: Number of Participants Who Passed Bladder Trial — 25; 39 participants
Phase 3 N=37 Bladder Scan of Residual Urine With New Catheter
Urinary Incontinence
Primary: Mean Residual Urine Volume — 12.4; 9.4 mL
N/A N=174 Recovery Support for Bladder Cancer Patients and Caregivers
Bladder Cancer · Patient Engagement · Patient Empowerment
Primary: Quality of Life Patient: The Functional Assessment of Cancer Therapy-Bladder Cancer-Cystectomy — 117.59; 118.70 Quality of Life Score — p=0.772
Phase 2 N=160 Preventing Urinary Tract Infection Post-Surgery
Urinary Tract Infection
Primary: Participants With Clinically-diagnosed and Treated UTI's. — 15; 30 participants
N/A N=108 Occlusion Balloon vs. 5FR Ureteral Catheter
Kidney Stones
Primary: Number of Participants With Ureteral Stone Fragments Identified Endoscopically — 2; 8 Participants
N/A N=491 Urinary Retention After Laparoscopic Inguinal Hernia Repair: Comparing the Use of the Intraoperative Urinary Catheter
Inguinal Hernia
Primary: Number of Participants With Post Operative Urinary Retention — 23; 21 Participants
Phase 4 N=154 Nitrofurantoin Prophylaxis During Catheter-managed Acute Urinary Retention After Pelvic Reconstructive Surgery
Pelvic Organ Prolapse
Primary: Number of Participants Experiencing Urinary Tract Infection Within 6 Weeks of Surgery — 13; 13 Participants — p=0.97
N/A N=36 Evaluation of Residual Urine After Intermittent Catheterisation
Healthy
Primary: Residual Urine Measured by Ultra Sound — 11; 6 ml — p=0.56
Phase 4 N=77 Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms
Flank Pain · Urinary Bladder, Overactive
Primary: Change in Post-ureteroscopy Stent-induced Pain — 4.61; 3.11 units on a scale
N/A N=234 Intraoperative Cone-beam CT for Percutaneous Nephrolithotomy
Nephrolithiasis
Primary: "Second Look" Rate — 4; 56; 56; 118 Participants — p=<0.01
Phase 2 N=61 Multifaceted Treatment of Catheter-related Urinary Tract Infection
Spinal Cord Injury · Neurogenic Bladder · Urinary Tract Infection
Primary: The Primary Efficacy Outcome of the Study is Response to Treatment Which Will be Assessed at the End of Therapy. Successful Response to Treatment is Defined as…
N/A N=107 Use of The Spanner Temporary Prostatic Stent as an Alternative to a Urinary Catheter to Achieve Bladder Drainage in Men
Urinary Retention
Primary: Number of Participants Who Achieved Post-void Residual (PVR) of ≤150 ml Over 90 Days — 79 Participants